Proteomics International Laboratories Share Price and Company Fundamentals
Last traded: Today at 5:38 AM
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia. The company was founded in 2001 and is based in Perth, Australia.
|Primary activities||Healthcare and Biotechnology/Life Sciences Tools and Services.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||QEII Medical Centre QQ Block 6 Verdun Street Nedlands Perth WA 6009 Australia|
|Phone / Fax||61 8 9389 1992 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Proteomics International Laboratories does not pay dividends.
As of Jul 2021, following are the company executives and directors listed on Proteomics International Laboratories.
|Dr. Richard John Lipscombe M.A., Ph.D., Ph.D., (London), MA (Oxford)||Co-Founder, MD & Director||299.23k|
|Ms. Jacqueline Gray||Chief Financial Officer|
|Mr. John Chuck Morrison||Head of Bus. Devel.|
|Mr. Vik Malik||Chief Commercialisation Officer|
|Ms. Karen Teresa Logan B.Com., FCIS, BCom, DipAppCorpGov, FFin, ACIS, AGI||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Proteomics International Laboratories is 126.25M and its enterprise value is 118.45M. The enterprise value to revenue ratio of PIQ is 49.67.
The PIQ's stocks Beta value is 1.12 making it 12% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Proteomics International Laboratories (PIQ)
Proteomics International Laboratories (ASX:PIQ) Frequently Asked Questions
1. What is Proteomics International Laboratories's Stock Symbol?
Proteomics International Laboratories trades on ASX under the ticker symbol "PIQ".
2. What is Proteomics International Laboratories's stock price today?
One share of PIQ stock can currently be purchased for approximately $1.2.
3. How can I contact Proteomics International Laboratories?
Proteomics International Laboratories's mailing address is QEII Medical Centre QQ Block 6 Verdun Street Nedlands Perth WA 6009 Australia. The company can be reached via phone at 61 8 9389 1992.
4. What is Proteomics International Laboratories's official website?
The official website of Proteomics International Laboratories is http://www.proteomics.com.au.
5. Which share registry manages Proteomics International Laboratories's stock?
Proteomics International Laboratories's stock is managed by AUTOMIC REGISTRY SERVICES.